Xbrane buys Primm Pharma; signs distribution deal for lead product with Pooyesh Darou

14 October 2015

Swedish pharmaceutical company Xbrane on Wednesday said it has acquired Italian firm Primm Pharma boosting its current portfolio to eight drug candidates and that the deal would raise the company’s potential annual revenue to $10 million.

Martin Åmark, chief executive of Xbrane, said: "Through the acquisition of Primm Pharma we are able to broaden our expertise within the field of high demand complex generics. Primm Pharma has unique expertise in microsphere-based drugs and a lead product Spherotide that we believe will become the world's first slow-release biogeneric for a sizable prostate cancer and endometriosis drug.”

The company also said it has completed a distribution deal for its lead biogeneric pharmaceutical Spherotide with the Iranian company Pooyesh Darou. No financial details were disclosed. The lead product Spherotide will primarily be used to treat prostate cancer and endometriosis and will be available in emerging markets from mid-2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK